Legal Representation
Attorney
Michael T. Smith
USPTO Deadlines
Next Deadline
1776 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-05-28)
Due Date
May 28, 2030
Grace Period Ends
November 28, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
34 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| May 28, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| May 28, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Mar 12, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 12, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Feb 21, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Feb 21, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Feb 8, 2024 | IUCN | S | NOTICE OF ALLOWANCE CANCELLED | Loading... |
| Feb 7, 2024 | JURT | T | JURISDICTION RESTORED TO EXAMINING ATTORNEY | Loading... |
| Feb 7, 2024 | PCBG | O | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | Loading... |
| Feb 6, 2024 | APET | A | ASSIGNED TO PETITION STAFF | Loading... |
| Jan 10, 2024 | TPAD | I | TEAS PETITION TO AMEND BASIS RECEIVED | Loading... |
| Dec 12, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Nov 9, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Nov 9, 2023 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Nov 9, 2023 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Nov 9, 2023 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Nov 9, 2023 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Oct 17, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Oct 17, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Sep 27, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Sep 12, 2023 | WOAG | I | WITHDRAWAL OF ATTORNEY GRANTED | Loading... |
| Sep 12, 2023 | WOAR | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED | Loading... |
| Sep 12, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 28, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 28, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 28, 2023 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Apr 14, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Mar 3, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Mar 3, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Mar 3, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Feb 25, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jun 14, 2022 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Jun 13, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jun 7, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Medicines for human purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; pharmaceutical preparations for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; drugs for medical purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; chemico-pharmaceutical preparations for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; chemical preparations for medical purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; biological preparations for medical purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; bulk medicines for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; biochemical medicines for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; chemical preparations for pharmaceutical purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; medicines in the nature of tablets for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; medicines for human purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders in the nature of capsule; injectable medicines for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders
Additional Information
Design Mark
The mark consists of a spherical design formed by three stacked offset curved lines on the bottom and three stacked offset curved dotted lines on the top with the word "YOCHANRA" to the right of the design.
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
005